Thu, Feb 27, 9:19 PM (130 days ago)
**Pacira BioSciences, Inc. (PCRX) 2024 Annual Report Summary** For the fiscal year ended December 31, 2024, Pacira BioSciences reported total revenues of $704.4 million, with EXPAREL contributing $549.0 million, representing 78% of total revenues. Net income was reported at $42.0 million, while operating expenses totaled $658.4 million. Earnings per share stood at $0.90. The company launched its 5x30 strategic growth plan, aiming for double-digit revenue growth and expansion of treatment offerings. Key products include EXPAREL, ZILRETTA, and iovera°, with ongoing investments in research and development. Risks include dependence on third-party reimbursements, competition from generics and alternative therapies, and regulatory challenges. The company faces significant debt obligations of $595.3 million, including convertible notes and a term loan, which may limit operational flexibility. Pacira's financial condition is affected by potential product liability claims and the need for ongoing compliance with stringent regulatory standards. Future growth relies on successful commercialization of existing products and the integration of acquired technologies, such as the recent GQ Bio acquisition. In conclusion, while Pacira shows promising revenue growth and strategic initiatives, it faces considerable risks and financial obligations that could impact future performance.